Blue Jet Healthcare Downgraded on Weak Execution, Pipeline Concerns
JPMorgan downgraded Blue Jet Healthcare to Underweight with a ₹330 target price, citing weak contrast media execution, bempedoic acid competitive threats, and a thin late-stage pipeline with no launches expected for two years.
Blue Jet Healthcare shares hit a 10 percent lower circuit on Monday, February 16th, reaching a low of ₹357.75 compared to its previous close of ₹397.45, after JPMorgan downgraded the company to Underweight and reduced its target price to ₹330 per share. The revised valuation indicates a potential downside of approximately 17 percent from Friday's closing price.
The downgrade followed the company's Q3 results, which showed revenue from operations declined by 40 percent year-over-year from ₹318 crore in Q3FY25 to ₹192 crore in Q3FY26. Net profit declined by 59 percent year-over-year from ₹99.0 crore in Q3FY25 to ₹40.2 crore in Q3FY26. The earnings per share for the quarterly period stood at ₹2.32, compared to ₹3.01 in the previous quarter. The December quarter results showed EBITDA falling 62.2 percent with margins contracting to 24.3 percent from 39 percent.
JPMorgan reduced its target multiple from 30x to 22x and cut earnings per share estimates for fiscal years 2026, 2027, and 2028 by 11 percent, 18 percent, and 23 percent, respectively. The company's market capitalization stood around ₹6,890 crore as of mid-February 2026.
The company's contrast media business has witnessed weak execution, declining at a 5 percent compound annual growth rate over FY23–26E due to the muted performance of its flagship product and the absence of meaningful new launches. The PI and API segment, especially bempedoic acid, is facing pressure amid customer destocking. Growth visibility remains uncertain as Esperion has guided for significant gross margin improvement, indicating reduced outsourcing opportunities, and is shifting European manufacturing to Daiichi Sankyo, which already works with other CDMO partners.
Merck & Co. is developing a superior oral PCSK9 inhibitor with added Lp(a) benefits, posing further competitive risk to the bempedoic acid franchise. The brokerage highlighted concerns around the company's weak late-stage pipeline, with new product launches expected only beyond the next two years.
JPMorgan emphasized high product concentration risk, as two products contribute nearly 70–75 percent of total revenue, making earnings vulnerable to demand or competitive disruptions. This dependency makes Blue Jet Healthcare particularly vulnerable to shifts in demand or competitive pressures affecting these specific products.
Blue Jet Healthcare is a specialty pharmaceutical and healthcare ingredients and intermediates company focused on niche, high-value products. Operating with a "Collaboration, Development, Manufacturing" approach, the company partners with global innovators and customers to deliver end-to-end CDMO solutions. As of FY25, the company has built a diversified portfolio of 51 commercialized products, supported by a total reaction capacity of 1,177.9 KL across three manufacturing facilities. The company reported a Fixed Asset Turnover ratio of 3.97x in FY25.
The company demonstrates a return on capital employed of 39.8 percent and return on equity of 30.2 percent. With a debt-to-equity ratio of 0.02, it operates with minimal financial leverage.